PCG 2026: India’s Billion Dose Challenge for Peptides and Complex Generics
MUMBAI, INDIA — Following the success of its inaugural edition, Mumbai Biocluster, a Section-8 not-for-profit institution under the Institute of Chemical Technology (ICT), Mumbai, has announced the second edition of the Peptides & Complex Generics Symposium (PCG 2026). The symposium will take place on 28–29 September 2026 at Aurika by Lemon Tree Hotels, Mumbai.
As the pharmaceutical industry rapidly expands beyond traditional generics into complex therapeutics such as peptides, oligonucleotides, and long-acting injectables, there is an increasing need for expertise across manufacturing, analytical characterization, regulatory science, and commercialization. PCG 2026 will bring together global experts, industry leaders, regulators, policy makers and researchers to address these challenges and accelerate innovation in complex therapeutics.
A signature addition to this year’s programme is the Billion Dose Challenge—an industry-led initiative exploring how India can manufacture and deliver complex therapeutics at population-scale while maintaining quality, affordability, and regulatory excellence. By placing this challenge at the centre of PCG 2026, Mumbai Biocluster aims to foster actionable strategies that strengthen India’s position as both an innovation hub and a global supplier of advanced medicines.
“India has already proven, it can make medicines affordable — the real test now is whether we can make complex therapeutics like peptides available at population scale, without compromising on quality or speed. The Billion Dose Challenge is our way of putting that question at the centre of the conversation, not at the margins. Through PCG 2026, we want to bring together the people who build, regulate, and finance these medicines, so that India moves from being a fast follower to a genuine architect of how the world manufactures complex therapeutics.”
— Dr. Ratnesh Jain, Founder & Director, Mumbai Biocluster
Key Highlights
- Plenary Discussions on the Billion Dose Challenge and Beyond China +1, building resilient global supply chains for complex therapeutics.
- Global Speakers from leading pharmaceutical companies, technology providers, and research organizations like CEM Scientific Private Limited,Consulate General of Switzerland and OneSource Specialty Pharma Limited sharing insights on peptide manufacturing, GLP-1 therapies, oligonucleotides, and regulatory science.
- Technical Workshops covering peptide purification and next-generation oligonucleotide facility design with practical, industry-focused training.
- Innovation Opportunities through abstract presentations, awards, travel grants, and recognition for young researchers.
- Molecule-to-Market Expo showcasing cutting-edge technologies from leading global and Indian life sciences company like Sartorius Stedim India Private Limited, Cytiva, Agilent Technologies India Private Limited, Invitron Advanced Analytics Private Limited, Hitachi High-Tech India Private Limited and more.
- Networking Platform connecting academia, industry, policymakers, startups, investors, and technology providers.
PCG 2026 offers participants an opportunity to gain scientific insights, discover emerging technologies, build strategic partnerships, and contribute to shaping the future of peptide and complex therapeutics.
PCG 2026 accelerates your journey from discovery to commercial impact.
Be a part of the dialogue that matters. Be a part of #PCG2026.
Registrations & Partnerships:
Registrations, poster submissions, and sponsorship opportunities are open. Visit: www.pcgsymposium.com
For partnership and exhibition enquiries, reach out to:
Ms. Simran Siddiqui, Marketing Associate. marketing.associate@mumbaibiocluster.org | +91 93727 10286
For registration queries, reach out to:
Tejal Khanna, Sales Executive. executive.sales@mumbaibiocluster.org | +91 93722 10650
Neha Gupta, Sales Executive. sales.executive@mumbaibiocluster.org | +91 87791 97872
Chaitya Shah, Sales Associate. sales.associate@mumbaibiocluster.org | +91 93213 84357
